NCT04869371

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

A Randomized, Controlled, Single Center Clinical Trial to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Androgen Deprivation Therapy Combined With Docetaxel for High Risk and Very High Risk Prostate Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Hongqian Guo · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.

Conditions

• Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Interventions

Type	Name	Description
DRUG	Docetaxel injection	75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
DRUG	Triptorelin Pamoate for Injectable Suspension	15mg every 12 weeks
DRUG	Prednisone Acetate Tablets	5 mg oral low dose prednisone, once daily

Timeline

• Start date: 2018-12-12
• Primary completion: 2020-12-01
• Completion: 2023-01-01
• First posted: 2021-05-03
• Last updated: 2022-12-29

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study